Humanwell Healthcare (Group) Co.,Ltd. (SHA:600079)

Market Cap	28.16B -15.6%
Revenue (ttm)	23.93B -5.1%
Net Income	1.90B +37.5%
EPS	1.17 +37.5%
Shares Out	1.63B
PE Ratio	14.74
Forward PE	11.72
Dividend	0.48 (2.76%)
Ex-Dividend Date	Aug 19, 2025

Volume	6,816,660
Open	17.35
Previous Close	17.39
Day's Range	17.20 - 17.38
52-Week Range	16.73 - 23.66
Beta	0.41
Analysts	Hold
Price Target	22.21 (+28.75%)
Earnings Date	Aug 25, 2026

About SHA:600079

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients who require opioid analgesia; nabuphine hydrochloride injection for use as an analgesic for anesthesia induction; alfentanil hydrochloride injec...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1988
• Employees: 17,153
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600079

Financial Performance

In 2025, SHA:600079's revenue was 23.96 billion, a decrease of -5.79% compared to the previous year's 25.44 billion. Earnings were 1.86 billion, an increase of 39.53%.